ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Coronavirus tests India's vaccine makers in R&D capability

Top player Serum ties up with US company to target product launch by Q2 next year

Indian vaccine manufacturers have been able to offer affordable vaccines to developing countries because they have the capacity to mass-produce. (Source photo courtesy of Zydus Cadila)

MUMBAI/NEW DELHI -- At least six Indian pharmaceutical companies have joined the global race to develop a novel coronavirus vaccine, giving a sector better known for making generic copies of drugs a platform to show its innovative capability.

The World Health Organization has listed three Indian companies -- Zydus Cadila, Serum Institute of India and Bharat Biotech -- that are working on a vaccine. In addition, Hyderabad-based companies Biological E and Indian Immunologicals as well as Bangalore-based Mynvax are also involved in development.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more